GBLI:NASDAQGlobal Indemnity Group, LLC Analysis
Data as of 2026-06-19 - not real-time
$25.34
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Global Indemnity Group (GBLI) is trading at its recent support level of $25.34, well below its 20‑day, 50‑day and 200‑day moving averages, indicating a pronounced bearish technical stance. However, the RSI of roughly 30 signals oversold conditions, and a rising volume trend suggests renewed buying interest, especially as the company announced a $0.35 per share distribution that may provide short‑term price support.
Fundamentally, GBLI appears markedly undervalued – its trailing PE of 10.8 is far below the industry average of 16.9, its price‑to‑book sits under 0.6, and the DCF‑derived fair value of $33.36 implies nearly 90% upside. The balance sheet is solid with modest debt, strong free cash flow, and a low beta indicating limited market volatility, though operating cash flow remains negative and revenue growth is flat, underscoring a value‑oriented, low‑growth profile.
Fundamentally, GBLI appears markedly undervalued – its trailing PE of 10.8 is far below the industry average of 16.9, its price‑to‑book sits under 0.6, and the DCF‑derived fair value of $33.36 implies nearly 90% upside. The balance sheet is solid with modest debt, strong free cash flow, and a low beta indicating limited market volatility, though operating cash flow remains negative and revenue growth is flat, underscoring a value‑oriented, low‑growth profile.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- Price at technical support with rising volume
- Oversold RSI indicating potential rebound
- Upcoming distribution providing immediate cash flow to shareholders
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation gap to DCF fair value
- Low PE and PB relative to peers
- Strong free cash flow and low debt enhancing financial resilience
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Limited revenue growth and modest profitability margins
- Sector exposure to underwriting cycles and regulatory changes
- Low beta and attractive valuation supporting a defensive stance
Key Metrics & Analysis
Financial Health
Revenue Growth0.50%
Profit Margin7.45%
P/E Ratio10.8
ROE4.83%
ROA1.63%
Debt/Equity1.12
P/B Ratio0.5
Op. Cash Flow$-11196000
Free Cash Flow$34.2M
Industry P/E16.9
Technical Analysis
TrendBearish
RSI30.5
Support$25.34
Resistance$27.39
MA 20$26.45
MA 50$27.25
MA 200$28.26
MACDBearish
VolumeIncreasing
Fear & Greed Index92.14
Valuation
Fair Value$33.36
Target Price$49.00
Upside/Downside93.37%
GradeUndervalued
TypeValue
Risk Assessment
Beta0.14
Volatility21.69%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.